Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ceftriaxone + Dextrose** is a combination of ceftriaxone sodium and dextrose injection. It belongs to the cephalosporin class of antibiotics and is used to treat various bacterial infections, including lower respiratory tract infections, skin and skin structure infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, and surgical prophylaxis. The mechanism of action involves inhibiting bacterial cell wall synthesis[9]. Ceftriaxone is administered intravenously over 30 minutes and should be used only when infections are proven or strongly suspected to be caused by susceptible bacteria[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone + dextrose.